Amantadine in Parkinson's disease: lymphocyte subsets and IL-2 secreting T cell precursor frequencies

• Published in: Experimental gerontology 2001-11, Vol.36 (10), p.1761-1771
• Main Authors: Tribl, G.G, Wöber, Ch, Schönborn, V, Brücke, T, Deecke, L, Panzer, S
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Alloimmune response; Amantadine - therapeutic use; Amantadine treatment; Antiparkinson Agents - therapeutic use; B cells; Female; Humans; Interleukin-2; Interleukin-2 - metabolism; Lymphocyte Count; Lymphocyte Subsets - pathology; Male; Middle Aged; Parkinson Disease - blood; Parkinson Disease - drug therapy; Parkinson Disease - pathology; Parkinson's disease; Stem Cells - pathology; T cells; T-Lymphocytes - metabolism; T-Lymphocytes - pathology
• ISSN: 0531-5565; 1873-6815
• DOI: 10.1016/S0531-5565(01)00128-0

The antiviral drug amantadine, that is effective in idiopathic Parkinson's disease (PD), may affect the composition and function of peripheral blood lymphocytes. In an explorative study, we therefore compared lymphocyte subpopulations and IL-2 secreting T cell precursors frequencies (HTLp-frequencies) in 15 PD patients without amantadine and six patients on long-term treatment. Five patients were investigated before and three months after the start of treatment. Group comparisons for long-term amantadine treatment showed no differences in subpopulations of B-, T-, and NK cells, and HTLp-frequencies. However, three months after initiation of treatment we noted in all five patients an increase of CD3+CD4+ and decrease of CD3+CD8+ cells, associated with an increase of the CD3+CD4+/CD3+CD8+ ratio. These changes had no effect on the HTLp-frequencies. Thus, at least for a short period of time, amantadine improves the T cell mediated immune system in PD patients.